Jackson Thornton Wealth Management LLC Buys Shares of 1,099 Medpace Holdings, Inc. $MEDP

Jackson Thornton Wealth Management LLC acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, according to its most recent filing with the SEC. The firm acquired 1,099 shares of the company’s stock, valued at approximately $584,000.

Other large investors have also bought and sold shares of the company. Quent Capital LLC purchased a new position in shares of Medpace in the 3rd quarter worth $25,000. Root Financial Partners LLC purchased a new position in Medpace in the 3rd quarter worth about $38,000. Geneos Wealth Management Inc. grew its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Employees Retirement System of Texas purchased a new stake in Medpace in the second quarter worth about $36,000. Finally, Wilmington Savings Fund Society FSB raised its holdings in shares of Medpace by 124.1% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 130 shares of the company’s stock valued at $67,000 after purchasing an additional 72 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Price Performance

Shares of Medpace stock opened at $596.63 on Tuesday. The business has a 50-day moving average of $582.94 and a 200-day moving average of $514.69. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92. The company has a market capitalization of $16.81 billion, a PE ratio of 41.62, a P/E/G ratio of 2.05 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period last year, the firm earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on MEDP shares. Robert W. Baird set a $613.00 price target on Medpace in a research note on Friday, October 24th. BMO Capital Markets assumed coverage on Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target for the company. Mizuho set a $660.00 price objective on Medpace in a report on Friday, January 9th. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Cowen reaffirmed a “sell” rating on shares of Medpace in a report on Friday, October 24th. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $491.27.

Insider Transactions at Medpace

In related news, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. This trade represents a 42.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Jesse J. Geiger sold 21,503 shares of the stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the sale, the president directly owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This represents a 58.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 387,925 shares of company stock worth $233,386,647. Insiders own 20.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.